<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-160156</identifier>
<setSpec>0213-005X</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">In vitro activity of a polyhexanide&#150;betaine solution against high-risk clones of multidrug-resistant nosocomial pathogens</dc:title>
<dc:description xml:lang="en">Objective: To determine the in vitro activity of a polyhexanide&#150;betaine solution against collection strains and multidrug-resistant (MDR) nosocomial isolates, including high-risk clones. Methods: We studied of 8 ATCC and 21 MDR clinical strains of Staphylococcus aureus, Enterococcus faecium, Enterococcus faecalis, Escherichia coli, Enterobacter cloacae, Klebsiella pneumoniae, Acinetobacter baumannii, and Pseudomonas aeruginosa, including the multiresistant high-risk clones. The MICs and MBCs of a 0.1% polyhexanide&#150;0.1% betaine solution were determined by microdilution. For each species, strains with the highest MICs were selected for further experiments. The dilution&#150;neutralization test (PrEN 12054) was performed by incubating bacterial inocula of 106CFU/mL for 1min with undiluted 0.1% polyhexanide&#150;betaine solution. The CFUs were counted after neutralization. Growth curves and time-kill curves at concentrations of 0.25, 1, 4, and 8×MIC, were performed. MICs of recovered strains were determined when regrowth was observed in time-kill studies after 24h of incubation. Strains with reduced susceptibility were selected by serial passage on plates with increasing concentrations of polyhexanide&#150;betaine, and MICs were determined. Results: Polyhexanide&#150;betaine MIC range was 0.5&#150;8mg/L. MBCs equalled or were 1 dilution higher than MICs. The dilution&#150;neutralization method showed total inoculum clearance of all strains. In time-kill curves, no regrowth was observed at 4×MIC, except for S. aureus (8×MIC). Increased MICs were not observed in time-kill curves, or after serial passages after exposure to polyhexanide&#150;betaine. Conclusions: Polyhexanide&#150;betaine presented bactericidal activity against all MDR clinical isolates tested, including high-risk clones, at significantly lower concentrations and time of activity than those commercially used (AU)</dc:description>
<dc:creator>López Rojas, Rafael</dc:creator>
<dc:creator>Fernández Cuenca, Felipe</dc:creator>
<dc:creator>Serrano Rocha, Lara</dc:creator>
<dc:creator>Pascual,  Álvaro</dc:creator>
<dc:language>en</dc:language>
<dc:description xml:lang="es">Objetivos: Determinar la actividad in vitro de una solución de polihexanida-betaína frente a una colección de cepas nosocomiales multirresistentes, incluyendo clones de alto riesgo. Métodos: Estudiamos 8 cepas ATCC y 21 cepas clínicas de Staphylococcus aureus, Enterococcus faecium, Enterococcus faecalis, Escherichia coli, Enterobactercloacae, Klebsiella pneumoniae, Acinetobacter baumannii y Pseudomonas aeruginosa, incluyendo clones de alto riesgo multirresistentes. Determinamos las CMI y las CMB de una solución 0,1% de polihexanida y 0,1% de betaína por microdilución. De cada especie, seleccionamos las cepas con mayores CMIs para los siguientes experimentos. Realizamos el test de dilución-neutralización (PrEN 12054) incubando 106UFC/ml 1min con solución 0,1% de polihexanida-betaína, calculando las UFCs tras un paso de neutralización. Realizamos curvas de crecimiento y de tiempo-muerte a concentraciones 0,25, 1, 4 y 8×CMI. Determinamos las CMIs de las cepas recuperadas tras recrecimiento a las 24h. Seleccionamos cepas con sensibilidad reducida tras pases seriados en placas con concentraciones crecientes de polihexanida-betaína y determinamos sus CMI. Resultados: El rango de CMI fue de 0,5&#150;8mg/l. Las CMBs fueron iguales o una dilución mayor. El test de dilución-neutralización presentó aclaramiento total del inóculo en todas las cepas. En las curvas de tiempo-muerte, no se observó recrecimiento a 4×CMI, excepto para S. aureus (8×CMI). No se incrementó la CMI ni aquí ni en los pases seriados con polihexanida-betaína. Conclusiones: Polihexanida-betaína presenta actividad bactericida frente a todas las cepas multirresistentes estudiadas, incluyendo clones de alto riesgo, a concentraciones y tiempos de exposición significativamente menores que los usados comercialmente (AU)</dc:description>
<dc:source>Enferm Infecc Microbiol Clin;35(1): 12-19, ene. 2017. graf, tab</dc:source>
<dc:identifier>ibc-160156</dc:identifier>
<dc:title xml:lang="es">Actividad in vitro de una solución de polihexanida-betaína frente a patógenos nosocomiales multirresistentes pertenecientes a clones de alto riesgo</dc:title>
<dc:subject>^d28477^s22046</dc:subject>
<dc:subject>^d32271</dc:subject>
<dc:subject>^d1646^s22079</dc:subject>
<dc:subject>^d19042</dc:subject>
<dc:subject>^d904^s22073</dc:subject>
<dc:subject>^d15344^s22054</dc:subject>
<dc:type>article</dc:type>
<dc:date>201701</dc:date>
</metadata>
</record>
</ibecs-document>
